Beyond amyloid-β and tau: A cell-based multivariate blood test (iCAP) for early Alzheimer’s detection

ABSTRACT: Abstract: Background: With amyloid-β (Aβ) therapies for Alzheimer’s disease (AD) under active debate, there is a need for diagnostic tools that reflect disease biology beyond Aβ and tau for early detection and for patient stratification. The indicator cell assay platform (iCAP) is a tool for blood-based diagnostics that uses standardized cells as biosensors to transduce complex circulating signals into gene-expression readouts, which are then used to train multivariate disease classifiers for precision medicine. We developed an iCAP for early detection of Alzheimer’s disease (AD-iCAP). Methods: In a retrospective study, AD-iCAP was developed by incubating banked plasma samples from patients with early-stage AD (mild cognitive impairment or mild dementia) and age-matched controls with standardized neurons; whole-transcriptome responses were measured and used train disease classifiers by machine learning. The assay was optimized and analytically validated. Patient AD-iCAP data were separated into a training set, external validation set and an independent test set and used to parameterize and test models. To minimize bias, modeling features were selected from a predefined (a priori) 84-gene panel derived from an independent AD-iCAP dataset generated using plasma from 5xFAD mice. Results: We developed AD-iCAP using 191 banked plasma samples across three cohorts. Performance was assessed in two held-out sets: an external validation set (n=82; AUC 0.64, 95% CI 0.51–0.78) and an independent test set (n=23, AUC 0.77, 95% CI 0.57–0.96). Systems biology analyses of differential response profiles showed concordance with postmortem AD brain transcriptomes and enrichment of AD-relevant pathways beyond amyloid, including cholesterol biosynthesis, synaptic structure/neurotransmission and NGF/TrkA signaling (FDR < 0.05). The final model’s features included AD-linked genes AKT3, GPR50, PALLD and RGMA, related to neuronal signaling and cytoskeletal/axon-guidance processes. Conclusions: AD-iCAP is a blood-based diagnostic for early-stage detection of AD. It outputs cell-based transcriptional profiles with disease-relevance that are induced by circulating factors. In retrospective, multi-cohort testing, it showed modest-to-good discrimination, supporting prospective confirmation in larger cohorts. Because its readout captures biology beyond amyloid and tau, it may provide complementary information for combined testing. The multivariate readout supports further development for patient stratification as Aβ-targeted therapies and alternatives evolve.

ORGANISM(S): Homo sapiens

PROVIDER: GSE312139 | GEO | 2025/12/02

REPOSITORIES: GEO